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1. Introduction 
Microangiopathy is a term which describes a disease in the small blood vessels of the 
circulatory tree. Thrombotic Microangiopathy (TMA) was a term firstly introduced by Simmers 
in 1952 which combined several related disorders that are associated with thrombus formation 
in distinct organs [1]. In this group of rare diseases, the pathologic presentation is dominated by 
coagulation disturbances and endothelial cell injury resulting in swelling or detachment of the 
endothelial cell from the basement membrane, intraluminal aggregation of platelets and 
mechanical injury to red blood cells leading to thrombocytopenia and organ ischemia [2, 3] (see 
Table 1). These features are really common to various disorders, however Thrombotic 
Thrombocytopenic Purpura (TTP) and the Hemolytic-Uremic Syndrome (HUS), represent the 
major and more investigated forms whose pathogenesis has been clarified only in the last three 
decades [2-4]. Both TTP and HUS occur at a frequency of approximately 1-6 cases per one 
million people, may affect children and adults, and may each have several distinct subtypes 
with overlapping symptoms, but caused by differing pathophysiologic mechanisms [5].  
Virtually all properties of the normal microvascular endothelium are altered in TMAs. 
Endothelial cells synthesize many substances involved in coagulation and fibrinolysis, 
including prostacyclin, nitric oxide (NO), thrombomodulin, tissue-type plasminogen 
activator inhibitor and von Willebrand factor (VWF) [2]. Leukocyte activation and 
complement consumption are also involved in TMAs pathogenesis [6, 7]. Particularly, an 
increase in vWF have been claimed to account for the loss of physiologic thrombo-resistance 
and for the consequent widespread platelet aggregation in vascular beds throughout the 
body, creating a cycle of vasoconstriction with platelet and fibrin deposition and further 
thrombus formation [3, 6-8].  
In this chapter we will focus our attention particularly on von Willebrand factor (VWF)-
mediated forms of TMAs.   
2. Von Willebrand factor: A multitask protein 
Von Willebrand factor (VWF) is an abundant plasma glycoprotein produced in all vascular 
endothelial cells [9] and megakaryocytes [10]. Mature VWF is a large multimeric protein 
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composed of a variable number of identical subunits, each consisting of 2050 amino acids 
residues. 
Differential diagnosis 
Relative 
incidence
Additional diagnostic clues and associated 
organ failure
Sepsis 60.2% 
Positive blood coltures, leucopenia may be 
present due to hemophagocytosis phenomena, 
fever, purpuric lesions, signs of consumption 
coagulopathy
DIC 29% 
Prolongation of PT and APTT, increase of d-
dimer levels, decrease of natural anticoagulants, 
neurological and renal ischemias
Massive hemorrhage 8% 
Low hemoglobin level, history of previous 
hemorrhage,  prolongation of PT and APTT, 
tachycardia and/or cardiovascular instability 
Thrombotic 
microangiopathies 
0.8% 
Coombs-negative hemolytic anemia, severe 
thrombocytopenia, schistocytes in peripheral 
blood smears, neurological and renal 
symptoms, fever, normality of blood 
coagulation assays  
Heparin-induced-
thrombocytopenia 
1.4 
Previous use of heparin, elevation of platelet 
count after discontinuation of heparin, arterial 
thrombosis with skin necrosis  
Table 1. Thrombocytopenia and organ failure: differential diagnosis in some clinical settings 
The VWF gene (VWF) is located at the tip of the short arm of human chromosome 12 (12p13.2), 
spans approximately 180 kb [11] and contains 52 exons. In addition to the VWF gene, a partial 
unprocessed VWF pseudogene is located on human chromosome 22q11.2 [12]. 
The primary translation product consists of 2813 amino acids, wich includes, in addition to the 
mature subunit, a signal peptide of 22 residues and  a large propeptide of 741 residues [13]. 
This protein sequence consists of repeated domains or motifs that are shared with other 
proteins. These are arranged in the sequence: D1-D2-D′-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK. 
The protein is remarkably rich in cysteine, and in the secreted protein all these residues appear 
to be paired in disulfide bonds [14]. The mature subunit is extensively glycosylated with 12 N-
linked and 10 O-linked oligosaccharides, and the propeptide has three more potential N-
glycosylation sites. The N-linked oligosaccharides of VWF are unusual compared to those of 
other plasma glycoproteins because they contain ABO blood group oligosaccharides [15]. 
The preproVWF undergoes a maturation process in the rough endoplasmatic reticulum 
(RER) and in the Golgi complex. In the RER a monomer of proVWF (275 kDa) forms dimers 
via disulfide bonds at the carboxyl terminus, and it is known as “tail-to-tail” dimerisation 
[14, 16].  Instead, in the apparatus of Golgi dimers form multimers through an additional 
disulfide bond near the amino terminus of the mature subunit (“head-to-head” 
multimerisation), yielding multimers that may exceed 20 million Da in size. Additional 
modifications in the Golgi include the proteolytic removal of the large VWF propeptide, the 
completion of N-linked and O-linked glycosylation and sulfation of certain N-linked 
oligosaccharides. 
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In endothelial cells, up to 95% of VWF is secreted constitutively, whereas the remainder is 
stored in cytoplasmic granules called Weibel-Palade bodies that are specific for endothelium 
[17, 18]. Similar storage are found at the periphery of platelet ǂ-granules [19]. VWF is 
released as unusually large multimers (UL-VWF), which can be up to approximately 20 000 
kDa in size [20, 21] and are the most adhesive and reactive form of VWF. UL-VWF form 
string-like structures attached to the endothelial cell surface, perhaps through interaction 
with P-selectin [22].  
Once secreted into the blood, multimers are subject to competing processes of clearance and 
of proteolysis by ADAMTS-13 (A Disintegrin-like And Metalloprotease with 
ThromboSpondin type 1 motif 13), a multidomain zinc metalloprotease that is remarkably 
specific for VWF [23-27]. VWF multimers are cleared with a half-life of 12–20 h [28, 29], by a 
mechanism that may not depend strongly on multimer size [30]. The molecules usually 
appear as tangled, condensed coils, but under fluid shear stress are extended, and UL-VWF 
strings are cleaved by ADAMTS-13 at the Tyr1605-Met1606 bond in the A2 domain [31] to 
generate the range of VWF multimer sizes that normally circulate in the blood. 
Hemostasis depends on the balanced participation of VWF, and this balance reflects a 
competition between the biosynthesis of large VWF multimers and their degradation by the 
ADAMTS-13. Defects in the secretion, assembly or intravascular clearance of VWF can cause 
severe bleeding disorders. Conversely, inability to cleave the newly released UL-VWF 
multimers [32-34] owing to hereditary or acquired deficiency of plasma ADAMTS-13 
activity may induce spontaneous VWF-dependent platelet adhesion and aggregation [35], 
leading to disseminated microvascular thrombosis as seen in patients with thrombotic 
thrombocytopenic purpura (TTP). So, mutations in VWF cause bleeding in VWD, and 
ADAMTS-13 deficiency can cause even more dramatic VWF-dependent thrombosis in TTP. 
VWF is not an enzyme and, thus, has no catalytic activity. VWF serves as the primary 
adhesive link between platelets and the subendothelium, and it also carries and stabilizes 
coagulation factor VIII (FVIII) in the circulation. It performs its hemostatic functions through 
binding to other proteins, in particular to factor VIII, to platelet surface glycoproteins 
(GPIbǂ and integrin ǂIIbǃ3), and to  various subendothelial components, such as collagens, 
proteoglycans and glucosaminoglycans. Binding sites for several of these physiologically 
important ligands have been localized in the VWF subunit sequence. The binding of VWF to 
platelets appears to be regulated by its initial interaction with connective tissue, and also by 
shear stress in flowing blood. Under the effect of shear forces (>30 dyn/cm 2),  VWF 
unfolding occurs and the protein exhibits an extended chain conformation oriented in the 
general direction of the shear stress field . The stretched VWF conformation favors also a 
process of self aggregation, responsible for the formation of a spider web network, 
particularly efficient in trapping of flowing platelets [36-39]. Thus, the effect of shear stress 
on conformational changes in VWF shows a close structure-function relationship in VWF for 
platelet adhesion and thrombus formation in arterial circulation, where high shear stress is 
present. 
VWF, beside its well known engagement in primary haemostasis, participates in other 
biological phenomena of particular relevance for the field of bacterial infection and 
leukocyte recruitment and extravasation. The induction of endovascular infections involves 
complex interactions between surface components on the invading organism and various 
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host determinants. Staphylococcus aureus is a major pathogen in endovascular infections, 
such as infective endocarditis, suppurative thrombophlebitis, or vascular or heart valve 
prosthetic infection. Intravascular infection due to Staphylococcus aureus requires 
colonization of subendothelium requires both attachment and resistance to detachment 
under shear conditions. It was demonstrated that VWF binds to, and promotes the surface 
adhesion of S. aureus. Staphylococcal protein A (Spa) has been identified as a staphylococcal 
adhesin, especially for the high molecular weight VWF multimers [40].  
The process of bacterial adhesion causes migration and activation of  PMNs that secrete 
enzymes and ROS to eliminate the pathogens. VWF is an important player in hemostasis but 
has also been suggested to mediate inflammatory processes. Petri and colleagues [41] found 
that VWF strongly promotes the extravasation of leukocytes from blood vessels in a strictly 
platelet and GpIb dependent way.  
Moreover, very recently, are emerging new functions of VWF, including a new link between 
hemostasis and angiogenesis [42]. Indeed, it was seen that the angiodysplasia can be 
associated with von Willebrand disease (VWD) [43, 44], these evidences confirm VWF as a 
protein with multiple vascular roles. 
3. Thrombotic thrombocytopenic purpura (TTP) 
Thrombotic thrombocytopenic purpura (TTP), also known as Moschcowitz syndrome,is a 
severe life-threatening syndrome mainly characterized by disseminated microthrombi that 
occlude terminal arterioles and capillaries in the microcirculation of multiple organs, most 
frequently of the brain [3, 7, 8, 45]. TTP is a rare condition with an incidence of about 4-6 per 
million people per year. The annual incidence of idiopathic TTP in western countries is 
approximately 4 per million. However, idiopathic TTP occurs more often in women and 
black/African-American people. Pregnant women and women in the postpartum period 
accounted for a notable portion (12-31%; about 1 each 25,000 pregnancies) of the cases in 
some studies. For this reason TTP predominantly affects female subjects between 10 and 40 
years old [5, 6]. 
In 1924 Eli Moschcowitz reported the first case of TTP describing a healthy 16-year-old girl 
suddenly admitted to Mount Sinai Hospital because of  weakness and pain of her arms, 
pallor, fever, few petechiae on her body, anemia, and leukocytosis. Four days later she 
developed left hemiparesis and facial paralysis, became comatose and died. An autopsy 
showed multiple thrombi in terminal arterioles and capillaries of the heart, brain, kidney, 
spleen, and liver [45].   
Clinically TTP presented with a pentad of signs and symptoms: thrombocytopenia, 
haemolytic anemia, fever, neurologic abnormalities, and renal failure [46, 47]. An increased 
numbers of megakaryocytes in bone marrow, alterations of erythrocytes (schistocytes), and 
elevated serum levels of lactate dehydrogenase (LDH) are other important features [48, 49].  
Clotting studies are usually normal. The typical fragmented red blood cells are probably 
produced as blood flows through turbulent areas of the microcirculation partially occluded 
by platelet aggregates. Therefore, the severity of these abnormalities reflects the extent of the 
microvascular aggregation of platelets and is responsible for microangiopathic haemolytic 
anemia.  Serum levels of LDH are extremely elevated as a consequence of haemolysis and 
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leakage from ischaemic or necrotic tissue cells [49]. Anemia is usually severe, hemoglobin 
levels less than 10 mg/dL being reported in 99% of subjects. Hyperbilirubinemia (mainly 
unconjugated), reticulocytosis, circulating free hemoglobin, and low or undetectable 
haptoglobin levels are additional aspecific indicators of the accelerated red cell disruption 
and production. Indeed, a negative Coombs test is needed to confirm the microangiopathic 
nature of the hemolysis [46, 47]. 
The two main types of TTP are inherited and acquired [50]. In most cases, TTP remains 
idiopathic, nevertheless several factors may play a role. These factors may include some 
diseases and conditions, such as pregnancy, postpartum period, cancer, HIV, infections, and 
autoimmune diseases; some medical procedures, such as surgery, total-body irradiation, 
and blood and marrow stem cell transplant and some drugs, such as chemotherapy, 
ticlopidine, clopidogrel, cyclosporine A, quinine and hormone therapy and estrogens [46-
50].   
Inherited TTP mainly affects newborns and children and is due to deficiencies in the activity 
of von Willebrand factor cleaving protease (ADAMTS-13), while acquired TTP is secondary 
to presence of auto-antibodies directed against ADAMTS-13 and mostly occurs in adults 
and older children [51].  In this latter form, IgG autoantibodies that inhibit plasma 
ADAMTS-13 activity can be detected in most of these patients, resulting in a transient, or 
intermittently recurrent, defect of immune regulation.  The IgG subclass distribution 
identifies IgG4 as the most frequent subtype (90%), followed by IgG1 (52%), IgG2 (50%) and 
IgG3 (33%) [52]. IgG4 was identified alone and also in combination with other 
immunoglobulin subclasses. In addition, the hypothesis was proposed that the identification 
of IgG subclasses may provide a useful parameter to predict disease recurrence [52].  
In 1982 Moake first found that patients with relapsing acquired or congenital TTP had 
circulating “unusually large” VWF multimers, while ultra-large VWF was absent from the 
plasma of healthy persons [33]. Moake proposed that these subjects lacked a VWF 
depolymerase, possibly a protease, that normally cleaved ultra-large VWF. Then this VWF-
cleaving protease was purified, and named ADAMTS-13 because it belonged to the recently 
discovered “a disintegrin-like and metalloprotease with thrombospondin repeats” family of 
metalloproteases (see paragraph above). 
In patients with TTP, the systemic clumping of platelets mediated by unusually large 
multimers of VWF  often results in platelet counts below 20,000/ µL during an acute 
episode. Ischemia of the brain is common, and renal dysfunction may also occur. However, 
a severe renal involvement in a patient with a diagnosis of TTP may be confused with HUS 
erasing clinical distinctions between these two disorders [45-50].  
A rare form of TTP, called Upshaw-Schülman syndrome, is genetically inherited as a 
dysfunction of ADAMTS-13 [46]. In these forms of TTP, the deficiency is probably inherited 
as an autosomal recessive trait.  It may appear initially in infancy or childhood and may 
recur as ‘chronic relapsing TTP’ episodes at about 3-week intervals.  The absent or severely 
reduced plasma ADAMTS-13 activity in familial TTP is a consequence of homozygous (or 
double heterozygous) mutations in both of the ADAMTS-13 alleles located on chromosome 
9q34 (frameshift and point mutations) [25]. Patients with this inherited ADAMTS-13 
deficiency may be surprisingly asymptomatic, but may develop a severe and life-
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threatening in all those clinical situations with increased von Willebrand factor levels, such 
as infection or pregnancy. In these patients episodes of TTP are reversed or prevented by the 
infusion of platelet-poor fresh-frozen plasma, cryoprecipitate-poor plasma 
(cryosupernatant), or plasma that has been treated with a mixture of an organic solvent and 
detergent [53, 54].  The infusion about every 2-3 weeks of normal plasma into familial TTP 
patients lacking effective enzyme production/release prevents, or reduces the frequency of, 
TTP episodes.  
Plasmapheresis is usually not required. The plasma half-life of infused ADAMTS-13 activity 
is about 2–4 days. Since a plasma level of only about 5% of ADAMTS 13 is sufficient to 
prevent or shorten episodes of TTP a gene therapy could  induce lasting remissions in 
children with the chronic relapsing form of the disease [55]. 
In most patients with a diagnosis of TTP, ADAMTS 13 activity is 0 or lower than 5 percent of 
normal. Really, ADAMTS-13 deficiency may vary from 0 to 100% across several studies [2, 5, 
6]. The cause of this variability may reflect differences in ADAMTS-13 assay methods. 
Moreover, patients with secondary TTP almost never have severe ADAMTS-13 deficiency. 
Thus, ADAMTS-13 deficiency more frequently identifies a large subset of patients with 
idiopathic TTP who suffer from VWF-dependent micro-vascular thrombosis. 
Furthermore, essentially all patients with a prior history of severe ADAMTS-13 deficiency 
will have it again when they relapse with TTP, whether they had normal ADAMTS-13 levels 
at some other time during remission. Thus, ADAMTS-13 testing may help to distinguish the 
different mechanisms of TMA in complex clinical situations.  
The mortality is almost 90% if untreated, but if treated, the mortality is reduced to 15% [6]. 
Adults and older children with acquired acute idiopathic thrombotic thrombocytopenic 
purpura require daily plasma exchange [5, 6]. Adults and some older children with acquired 
ADAMTS-13 autoantibody-mediated TTP require daily plasma exchange until remission. 
Plasma exchange allows about 90 percent of these patients to survive an episode of 
thrombotic thrombocytopenic purpura, usually without permanent organ damage [54].  The 
plasma exchange has several beneficial effects such as removing fluid making it possible to 
substitute with a high volume of plasma to increase the ADAMTS 13 activity; another effect 
is to reduce the extent of cytokines and other pro-inflammatory factors that mayleado to 
VWF production and a further effect is to remove antibodies that are involved in the 
process. 
Some patients with acquired acute idiopathic thrombotic thrombocytopenic purpura and 
high titers of antibodies against ADAMTS 13 do not respond to plasma exchange alone [54]. 
For patients with idiopathic TTP, ADAMTS-13 deficiency is a biomarker for a high risk of 
relapsing disease.  In general, patients with idiopathic TTP usually respond to plasma 
exchange and those with secondary TTP do not.  The value of plasma therapy was 
demonstrated conclusively in a randomized, prospective comparison of plasma infusion 
and plasma exchange for the treatment of adults with TTP. Survival at 6 months was 78% 
with plasma exchange and 63% with plasma infusion, a significant difference in favor of 
plasma exchange (P = .036) [54]. Because of this trial, standard treatment for TTP today 
includes plasma exchange at 40 to 60 mL/kg daily until the patient has a normal platelet 
count and a normal LDH, and any nonfocal neurologic deficits have resolved. If plasma 
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exchange cannot be performed for some reason, patients may be treated instead with 
plasma infusion at up to 30 mL/kg daily, provided they can tolerate the fluid load.  
It may be possible to interfere with autoantibody production through treatment with 
glucocorticoids or splenectomy [56] Rituximab, the monoclonal antibody against CD20 on B-
lymphocytes, represent another important possible strategy in these patient [57-59].  
In this setting, rituximab appears to be effective at normalizing ADAMTS-13 levels and 
inducing durable remissions. Published small series and case reports have described 
approximately 100 patients with refractory or relapsing idiopathic TTP treated with 
rituximab, usually at doses of 375 mg/m2 weekly for an average of 4 doses. Approximately 
95% of reported patients have had a complete clinical and laboratory responses within 1 to 3 
weeks of starting treatment, including a normal ADAMTS-13 level and disappearance of 
anti-ADAMTS-13 antibodies [58, 60].  However, secondary infections and side effects should 
cause caution in the use of rituximab. This has caused FDA to stop an ongoing randomized 
study, the STAR-study, in the US due to serious adverse events in the rituximab arm [61].  
Mild acute reactions to rituximab infusions were controlled by premedication with steroids, 
antihistamines, and analgesics.   
Relapses have been infrequent, occurring in approximately 10% of patients after intervals of 
9 months to 4 years. These reports have all the limitations and potential biases of case series, 
and they should be interpreted cautiously. In particular, judging the efficacy of rituximab is 
difficult because patients usually receive multiple different treatments. Nevertheless, 
rituximab seems to rescue most patients with refractory or relapsing idiopathic TTP. 
Moreover, by abolishing autoantibody production, adjuvant rituximab at first diagnosis 
(combined with plasma exchange) might further improve outcomes by shortening the 
duration of plasma exchange, reducing early mortality, and preventing relapses.  
ADAMTS-13 has been partially purified and produced in recombinant active form for 
possible eventual therapeutic use [5, 6]. Because plasma ADAMTS-13 levels of only about 
5% is often sufficient to prevent or truncate TTP episodes, gene therapy may eventually 
extend remissions in familial TTP patients. Another possible new therapy is the infusion of 
an oligonucleotide aptamer designed to block the adhesion of platelet GP1ba receptors to A1 
domains in the VWF monomeric subunits of VWF strings. 
In the absence of life-threatening hemorrhage or intracranial bleeding, it is prudent to avoid 
platelet transfusions, which can exacerbate microvascular thrombosis. Aspirin may provoke 
hemorrhagic complications in patients with severe thrombocytopenia.  Currently, according to 
main guidelines, an adult patient who has a suspected  acquired syndrome that could be either 
thrombotic thrombocytopenic purpura or the hemolytic–uremic syndrome should be 
presumed to have thrombotic thrombocytopenic purpura, and plasma exchange should be 
initiated as soon as possible.  
4. Haemolitic uremic syndrome (HUS) 
Besides TTP, endothelial cells can be stimulated to secrete long VWF strings by inflammatory 
cytokines: tumour necrosis factor-alpha, interleukin (IL)-8 and IL-6, bacterial-produced toxins 
and oestrogen [2-7]. Therefore all those diseases or clinical conditions that contribute to this  
pathway could be responsible for a VWF mediated TMAs or predispose to this disorder. 
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Also HUS is characterized by low platelet count and microangiopathic hemolytic anemia 
due to platelet–fibrin thrombi occluding predominantly the renal circulation [4, 62, 63]. The 
most common of HUS, so-called typical HUS, affects about 70-80% of all HUS cases, mainly 
children and occurs in 9 to 30 percent of infected children about a week after an episode of 
bloody diarrhea caused by enterohaemorrhagic gram-negative Escherichia coli that produce 
Shiga toxin (e.g., Escherichia coli of serotype 0157:H7) [63]. This bacteria is found in manure, 
water troughs, and other places in farms, which may explain the increased risk of infection 
observed in people living in rural areas. The microorganism is transmitted to humans by 
food and water, directly from person to person and occasionally through occupational 
exposure. Fruits and vegetables may be contaminated and have been implicated in several 
outbreaks. Water-borne outbreaks have occurred as a result of drinking and swimming in 
unchlorinated water. Person-to-person transmission has been reported in daycare and 
chronic-care facilities [64, 65].  
Also Schigella dysenteriae type 1 can be responsible for a toxin involved in typical HUS.  
Finally, rare, familial types of HUS may be caused by deficient quantity or defective 
function of a regulatory protein in the alternative complement pathway;  or, more rarely, by 
defective intracellular cobalamin reduction/cofactor function.  
As in TTP, in typical HUS large multimers of von Willebrand factor can be produced by  
endothelial cells due to E.coli Shiga toxin1 production. This toxin stimulates the rapid and 
profuse secretion of long VWF multimeric strings from endothelial cells, including glomerular 
microvascular endothelial cells.  The initial and progressive platelet adhesion to long VWF 
strings may explain the glomerular microvascular occlusion and acute renal failure.  
However,  unlike TTP, HUS is not usually associated with the absence or severe reduction of 
plasma ADAMTS 13 activity. On the contrary, atypical HUS (aHUS), identified in about 10–
15% of patients, affecting more often adults,  has genetic causes and is frequently associated 
with gene mutations of complement regulators or components that form the alternative 
pathway convertase C3bBb, but is not a VWF mediated TMA.  Childhood Shiga toxin-E. 
coli–associated HUS usually recovers spontaneously and does not require plasma therapy 
[66, 67].  
5. Other secondary VWF-mediated TMAs  
There are many secondary causes of TMAs; many of them could mimic TTP or HUS. 
More recent data indicate that low or zero ADAMTS 13 activity is not confined to TTP and 
can even be found in a number of diseases associated with an increased tendency to 
thrombosis. Plasma ADAMTS-13 activity is often reduced below normal in liver disease, 
disseminated malignancies, chronic metabolic and inflammatory conditions, pregnancy and 
newborns [5, 6]. With the exception of the occasional peri-partum women who develop 
overt TTP, the ADAMTS-13 activity in these conditions is not reduced to the extremely low 
values (i.e., <5-10% of normal) found in patients with familial or acquired autoantibody 
mediated TTP. 
Moreover, HUS/TTP form complicates immune diseases, in particular systemic lupus 
erythematosus, and increasingly is reported in association with the antiphospholipid 
syndrome [6].  
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Indeed, von Willebrand factor's susceptibility to fragmentation increases in response to 
rising levels of shear stress, which induces protein unfolding and makes vWF proteolytic 
cleavage sites more accessible to ADAMTS-13. It is speculated that enhanced shear stress in 
the severely narrowed damaged microvessels accounts for the abnormal vWF fragmentation 
observed during an acute inflammation. Evidence of increased capacity of fragmented vWF 
to bind receptors on activated platelets suggests that shear stress-induced vWF 
fragmentation may contribute to maintain and further spread microvascular thrombosis. In 
addition, or alternatively, the accentuated secretion of long VWF multimeric strings by 
endothelial cells stimulated by oestrogen or inflammatory cytokines may be required to 
provoke TMAs in some patients with very low plasma ADAMTS-13 values.  
Plasmapheresis should always be attempted in secondary TMAs  even though the efficacy 
has to be demonstrated.  
6. TMAS associated to drugs 
Cyclosporine, a cyclic nonapeptide, and tacrolimus, a macrolide, inhibit protein 
phosphatase 2B (calcineurin) in immune and endothelial cells. Cyclosporine- or tacrolimus-
treated endothelial cells secrete long VWF multimeric strings. The latter process may slowly 
overwhelm the capacity of ADAMTS-13 to defend the microvasculature against platelet 
thrombotic occlusion and thrombotic 
Microangiopathy [57, 59, 68]. There are some analogies with the pathophysiology both of 
diarrhoea-associated HUS and of sepsis/disseminated intravascular coagulation 
(DIC)/renal failure. In sepsis/DIC/renal failure, there is cytokine-stimulated VWF string 
secretion from stimulated endothelial cells associated with the partial consumption of 
plasma ADAMTS-13. Treatment for transplantation-immunosuppression-induced or 
chemotherapy–radiotherapy associated thrombotic microangiopathy is, to date, limited to 
supportive care and the discontinuation of any putative offending drug.  
Ticlopidine and clopidogrel have been associated with the development of HUS/TTP, but 
this event is rare (1 in 1600 patients treated with ticlopidine after cardiac stenting). These 
drugs are structurally related derivatives of thienopyridine and act by blocking an 
adenosine diphosphate-binding site on platelets, which inhibits the expression of the 
glycoprotein IIb/IIIa receptor in the high-affinity configuration that binds fibrinogen and 
large VWF multimers. 
Why these two drugs cause TTP is not fully clear, but of great interest, as patients with 
ticlopidine- or clopidogrel-associated TTP have a deficiency of VWF-cleaving protease 
activity in plasma that appears quite comparable to the deficiency observed in idiopathic 
TTP [69-71]. Probably, these drugs, such as quinine, should be associated with development 
of antibodies against ADAMTS 13 and in these patients plasma exchange is indicated [69, 
71, 72].  
7. The role of VWF in other arterial thrombotic diseases 
It has been suggested that VWF plays an important role in the pathogenesis of arterial 
thrombotic disorders. Previous studies have shown the relevance of platelets and VWF in 
the initiation of atherosclerotic plaque formation. Both inactivation of VWF and inhibition of 
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VWF-GP1b interaction delay the formation of fatty streaks VWF. From a biological 
standpoint, it is likely that VWF contributes to the pathogenesis of early atherosclerotic 
lesions. Hence, many studies have investigated the association between VWF plasma levels 
and the subsequent risk of cardiovascular disease. In the ARIC study, the relative risk (RR) 
for coronary artery disease (CHD) for the highest vs. the lowest tertiles of VWF levels was 
approximately 1.3 [73, 74]. Moreover, VWF was found to play a relevant role in thrombotic 
microangiopathies occurring in diabetes mellitus [75]. More recently, compelling evidence 
has emerged about the association of high VWF levels with occurrence of ischemic stroke, 
particularly in the cardioembolic and cryptogenetic subtypes [76, 77]. On  the basis of the 
known association between micro- and macroangiopathy in the brain circulation [78], we 
can speculate that high levels of VWF may contribute to the development of cerebral 
micrangiopathies, responsible for pathological lesions such as lipohyalinosis and 
fribrohyalinosis [79] that may evolve toward various types of ischemic stroke [77].       
8. Prospectives and future directions 
TMA is the result of various etiological causes and pathologic reactions with various clinical 
entities.  Fortunatelly, TMAs are a rare group of disorders and  number of patients invoved 
is usually too low to sustain an adequately powered study to compare different diagnostic 
and treatment stategies. Certainly, it is important to focus on a thorough history including 
the family history when deciding on a diagnostics. Particularly in TTP several promising 
multicenter trials are in progress and prospective observational studies and multicentric 
registries are enrolling adult and pediatric patients for longitudinal measurements of 
ADAMTS-13 activity, antigen, and autoantibodies, and ADAMTS-13 gene sequencing, for 
evaluating different treatments such as rituximab plus plasma exchange.  These trials will 
address whether rituximab is best used as adjuvant or salvage therapy [80]. Because severe 
ADAMTS-13 deficiency will not be required for participation, this trial will include some 
patients with idiopathic TTP who do not have severe ADAMTS-13 deficiency, and the 
results should indicate whether such patients differ fundamentally from those with severe 
ADAMTS-13 deficiency in their response to plasma exchange, incidence of relapse, and 
response to rituximab. Moreover, these trials should clearly demonstrate whether rapid 
ADAMTS-13 assays could be useful for diagnosis or to guide therapy. Furthermore, 
ADAMTS-13 deficiency is not responsible for all cases of TMAs, and all the reserchers 
should look forward to recognizing and characterizing other causes, leading to 
understanding underlying unknown pathophysiologic mechanisms. At the moment, 
analysis of ADAMTS-13 and ADAMTS-13-antibodies may help to decide about continued 
therapy. 
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